筛选条件 共查询到16条结果
排序方式
Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy

期刊: LANCET HAEMATOLOGY, 2020; 7 (3)

Pregnancy-associated pulmonary embolism is one of the leading causes of maternal mortality. Diagnosis of pulmonary embolism in pregnancy is challengin......

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

期刊: LANCET HAEMATOLOGY, 2020; 7 (5)

Background Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infus......

Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study

期刊: LANCET HAEMATOLOGY, 2020; 7 (7)

Background Sickle cell disease is highly prevalent in sub-Saharan Africa, where it accounts for substantial morbidity and mortality. Newborn screening......

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

期刊: LANCET HAEMATOLOGY, 2020; 7 (9)

Background: COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important feat......

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

期刊: LANCET HAEMATOLOGY, 2019; 6 (1)

Background Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD......

JIF:11.99

Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

期刊: LANCET HAEMATOLOGY, 2019; 6 (6)

Background Anthracycline dose optimisation in the treatment of diffuse large B-cell lymphoma has rarely been tested. We aimed to find out whether R-CE......

JIF:11.99

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

期刊: LANCET HAEMATOLOGY, 2019; 6 (10)

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been shown to have activity in patients with relap......

JIF:11.99

Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial

期刊: LANCET HAEMATOLOGY, 2018; 5 (6)

Background The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patient......

JIF:11.99

共16条页码: 1/2页15条/页
打开APP